RxDoctor Payments Data

Nathan Nepo

Family · Mission Hills, CANPI 1194416255

Payments from drug & device makers

$3,468in general payments, 2019–2025

Across 105 payments — averaging $33.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$551
  • Aurinia Pharma U.S., Inc.$285
  • GSK$206
  • Lilly USA, LLC$196
  • Bayer$177
  • plus $860 from 13 others

What the payments were for

  • Food & beverage$3,468100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,468 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$19,822
Medicare patients
81
Services billed
165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol79$48,687
JardianceEmpagliflozin25$18,908
VeltassaPatiromer Calcium Sorbitex27$18,679
LokelmaSodium Zirconium Cyclosilicate29$14,456
Febuxostat16$1,836
Nifedipine ErNifedipine47$1,349
Olmesartan Medoxomil100$1,261
Hydralazine Hcl129$1,231
Losartan Potassium117$979
Chlorthalidone103$813
Allopurinol126$517
Furosemide162$506
Isosorbide Mononitrate ErIsosorbide Mononitrate33$373
Bumetanide22$275
Amlodipine Besylate61$207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$551$63,143108 claims
Boehringer IngelheimJardiance$64$18,90825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Mission Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →